Federal funding uncertainty and vaccine policy top child neurology's September agenda

Congress extended federal funding only through December 11, 2026, punting FY 2027 appropriations to a post-election lame-duck session. For pediatric neurologists and researchers, that uncertainty is more than a budget headache — it puts NIH grant continuity and long-term research planning at risk for some of medicine's most vulnerable patients.

The Child Neurology Society (CNS) isn't sitting on the sidelines. On September 15, CNS submitted formal comments to HHS calling for clear, evidence-based vaccine recommendations and timely immunization protocols — especially for children with complex neurological conditions, who face heightened risks from vaccine-preventable diseases. CNS representatives also met directly with Sen. Tammy Duckworth's office on September 29 to press federal priorities including sustained NIH funding, rare neurological disease support, and continued telehealth access.

Key Takeaways:

• Federal funding uncertainty through the lame-duck session poses real risks to pediatric research pipelines
• CNS is actively advocating for evidence-based vaccine guidance tailored to children with neurological conditions
• Telehealth access and rare disease funding remain top legislative priorities for child neurology advocates

Why it matters: With pediatric neurological conditions often underfunded and underrepresented in policy discussions, CNS's proactive engagement on Capitol Hill signals the stakes — and the urgency — of keeping these issues front and center as federal budget battles unfold.